Paper Details

  1. Home
  2. Paper Details

Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

Author: AmadoriSergio, BrocciaGiorgio, FeremansWalter, FilletGeorge, JehnUlrich, LeoneGiuseppe, MeloniGiovanna, RioBernard, SuciuStefan, ThomasXavier, VignettiMarco, de WitteTheo

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The best treatment after remission for older adults with acute myeloid leukemia (AML) is still unclear. Recent studies show that using a patient's own stem cells (autologous peripheral blood stem cell transplantation) is possible in this group. This study examines the outcomes of this treatment approach in older adults who achieved remission and consolidation treatment in a clinical trial.
Paper Details　
Original Abstract of the Article :
The optimal post-remission treatment for elderly patients with acute myeloid leukemia (AML) is presently unknown. Recent studies have reported the feasibility of autologous peripheral blood stem cell transplantation (PBSCT) in this population. We evaluate the outcome of this post-remission approach ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3324/haematol.10552

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of AML Treatment: A Study of Elderly Patients

The treatment of acute myeloid leukemia (AML) is a complex and evolving landscape, particularly in elderly patients. This study explores the use of autologous peripheral blood stem cell transplantation (PBSCT) as a post-remission treatment for elderly AML patients. Like a seasoned desert explorer, the researchers sought to uncover the effectiveness of this approach in a challenging environment. They analyzed data from the EORTC-GIMEMA AML-13 trial, focusing on the outcomes of PBSCT after complete remission and consolidation in patients aged 61-70 years. The findings of this study provide valuable insights into the potential benefits of PBSCT as a post-remission strategy for this patient population.

PBSCT: A Potential Oasis in the AML Desert

The results of this study suggest that PBSCT may be a viable option for elderly patients with AML who achieve complete remission. The study highlighted the importance of considering the individual patient's characteristics and the potential benefits and risks associated with this treatment approach.

Navigating AML Treatment: A Collaborative Approach

The treatment of AML, especially in elderly patients, is a complex journey. This study highlights the importance of a collaborative approach, involving a multidisciplinary team of experts to navigate the best treatment options for each individual. Understanding the potential risks and benefits of different treatment strategies is crucial for ensuring the best possible outcomes for these patients.

Dr. Camel's Conclusion

This study is like a camel caravan trekking through the challenging terrain of AML treatment, seeking the best path for elderly patients. By investigating the use of autologous peripheral blood stem cell transplantation (PBSCT) after remission, the researchers offer valuable insights into this complex landscape. Their findings highlight the importance of personalized medicine and collaborative care in navigating the shifting sands of AML treatment.
Date :
  1. Date Completed 2007-04-25
  2. Date Revised 2019-06-08
Further Info :

Pubmed ID

17339189

DOI: Digital Object Identifier

10.3324/haematol.10552

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.